Literature DB >> 23836681

Increased asthma risk and impaired quality of life after bronchiolitis or pneumonia in infancy.

Katri Backman1, Eija Piippo-Savolainen, Hertta Ollikainen, Heikki Koskela, Matti Korppi.   

Abstract

BACKGROUND: Recent studies have revealed that adulthood asthma has its origin in early childhood. AIM: The aim of the present study was to evaluate the prevalence of asthma and respiratory health-related quality of life in adults 30 years after hospitalization for bronchiolitis or pneumonia in infancy.
METHODS: Patients who were hospitalized for bronchiolitis or pneumonia at age under 24 months in 1981-1982 have been followed in repeated visits. In 2010, 48 of the 83 former patients with bronchiolitis (57.8%), 22 of the 44 former patients with pneumonia (50.0%), and 138 matched controls participated in the clinical study at the age of 28-31 years. The participants completed a structured questionnaire on respiratory symptoms, the Saint George's Respiratory Questionnaire (SGRQ), and underwent 2-week peak expiratory flow (PEF) monitoring. Asthma was defined as doctor-diagnosed and self-reported asthma based on doctor-prescribed medication for asthma, the presence of asthma-presumptive symptoms, and the results of home PEF monitoring.
RESULTS: Both doctor-diagnosed asthma (31.3% vs. 10.9% adjusted P = 0.002) and self-reported asthma (35.4% vs. 14.5% 0.003), as well as repeated on-demand use of bronchodilators (35.4% vs. 14.5% 0.002), and regular use of inhaled corticosteroids (20.8% vs. 8.7% 0.023) were more common in former bronchiolitis patients than in controls. Former bronchiolitis and pneumonia patients had higher total SGRQ scores than controls. The median scores were 5.4 (IQ(25-75) 0.0-14.7, P < 0.001) in bronchiolitis group, 4.9 (1.3-14.8, 0.012) in pneumonia group compared to controls 1.5 (0.0-6.0).
CONCLUSION: Hospitalization for bronchiolitis in infancy is associated with an increased risk of asthma, and an increased use of asthma medication in adulthood at the age of 28-31 years. Impaired respiratory health-related quality of life in adulthood as measured by the SGRQ is present after bronchiolitis and pneumonia in infancy.
© 2013 Wiley Periodicals, Inc.

Entities:  

Keywords:  Saint George's Respiratory Questionnaire; adulthood; child; outcome; prediction; wheezing

Mesh:

Year:  2013        PMID: 23836681     DOI: 10.1002/ppul.22842

Source DB:  PubMed          Journal:  Pediatr Pulmonol        ISSN: 1099-0496


  13 in total

1.  Risk of current asthma among adult smokers with respiratory syncytial virus illnesses in early life.

Authors:  Nipasiri Voraphani; Debra A Stern; Anne L Wright; Stefano Guerra; Wayne J Morgan; Fernando D Martinez
Journal:  Am J Respir Crit Care Med       Date:  2014-08-15       Impact factor: 21.405

2.  Inter-society consensus document on treatment and prevention of bronchiolitis in newborns and infants.

Authors:  Eugenio Baraldi; Marcello Lanari; Paolo Manzoni; Giovanni A Rossi; Silvia Vandini; Alessandro Rimini; Costantino Romagnoli; Pierluigi Colonna; Andrea Biondi; Paolo Biban; Giampietro Chiamenti; Roberto Bernardini; Marina Picca; Marco Cappa; Giuseppe Magazzù; Carlo Catassi; Antonio Francesco Urbino; Luigi Memo; Gianpaolo Donzelli; Carlo Minetti; Francesco Paravati; Giuseppe Di Mauro; Filippo Festini; Susanna Esposito; Giovanni Corsello
Journal:  Ital J Pediatr       Date:  2014-10-24       Impact factor: 2.638

3.  Impact of hospitalizations for bronchiolitis in preterm infants on long-term health care costs in Italy: a retrospective case-control study.

Authors:  Daniela Paola Roggeri; Alessandro Roggeri; Elisa Rossi; Salvatore Cataudella; Nello Martini
Journal:  Clinicoecon Outcomes Res       Date:  2016-08-04

4.  Effects of Macrolide Treatment during the Hospitalization of Children with Childhood Wheezing Disease: A Systematic Review and Meta-Analysis.

Authors:  Chien-Yu Lin; Tzu-Lin Yeh; Shu-Jung Liu; Hsin-Hui Lin; Yu-Jyun Cheng; Hua-His Hung; Mu-Chieh Tsai; Jui-Ming Liu; Wei-Te Lei
Journal:  J Clin Med       Date:  2018-11-09       Impact factor: 4.241

5.  Association between early viral LRTI and subsequent wheezing development, a meta-analysis and sensitivity analyses for studies comparable for confounding factors.

Authors:  Sebastien Kenmoe; Arnol Bowo-Ngandji; Cyprien Kengne-Nde; Jean Thierry Ebogo-Belobo; Donatien Serge Mbaga; Gadji Mahamat; Cynthia Paola Demeni Emoh; Richard Njouom
Journal:  PLoS One       Date:  2021-04-15       Impact factor: 3.240

6.  The Associations of Caesarean Delivery With Risk of Wheezing Diseases and Changes of T Cells in Children.

Authors:  Jilei Lin; Shuhua Yuan; Bin Dong; Jing Zhang; Lei Zhang; Jinhong Wu; Jiande Chen; Mingyu Tang; Bin Zhang; Hansong Wang; Yuanyuan Dai; Shijian Liu; Yabin Hu; Xinyi Qi; Liangye Xu; Liebin Zhao; Yong Yin
Journal:  Front Immunol       Date:  2021-12-14       Impact factor: 7.561

Review 7.  Revised recommendations concerning palivizumab prophylaxis for respiratory syncytial virus (RSV).

Authors:  Lina Bollani; Eugenio Baraldi; Gaetano Chirico; Andrea Dotta; Marcello Lanari; Antonello Del Vecchio; Paolo Manzoni; Antonio Boldrini; Piermichele Paolillo; Sandra Di Fabio; Luigi Orfeo; Mauro Stronati; Costantino Romagnoli
Journal:  Ital J Pediatr       Date:  2015-12-15       Impact factor: 2.638

8.  The severity of acute bronchiolitis in infants was associated with quality of life nine months later.

Authors:  Leif Bjarte Rolfsjord; Håvard Ove Skjerven; Kai-Håkon Carlsen; Petter Mowinckel; Karen Eline Stensby Bains; Egil Bakkeheim; Karin C Lødrup Carlsen
Journal:  Acta Paediatr       Date:  2016-04-13       Impact factor: 2.299

Review 9.  Pediatric Asthma and Viral Infection.

Authors:  M Luz Garcia-Garcia; Cristina Calvo Rey; Teresa Del Rosal Rabes
Journal:  Arch Bronconeumol       Date:  2016-01-04       Impact factor: 4.872

10.  Association between early bronchiolitis and the development of childhood asthma: a meta-analysis.

Authors:  Guizuo Wang; Dong Han; Zhengdong Jiang; Manxiang Li; Shumei Yang; Lu Liu
Journal:  BMJ Open       Date:  2021-05-28       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.